Tradestie Institutional Equity Comparison Engine

SANA vs ERAS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ERAS Overall Edge

ERAS Captures Institutional Edge (3โ€“0 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Erasca, Inc. Common Stock (ERAS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SANA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ERAS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SANA sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against ERAS sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SANA N/M vs ERAS N/M Fwd P/E
Growth & Margin Winner ERAS
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner ERAS
1Y -48.6% vs +494.9% ยท 52W Pos 1% vs 58%
Options & Structure Winner ERAS
BREAKDOWN (4th %ile IV) vs BREAKDOWN (6th %ile IV)
SANA NASDAQ
Sana Biotechnology, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.88
-6.93% 1D
Market Cap $605.3M
1M Return -17.18%
1Y Return -48.63%
Forward P/E N/M
Unified AI Score
44.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 66.0 Mom 60.0
ERAS NASDAQ
Erasca, Inc. Common Stock
Pharmaceutical Preparations
$15.11
-3.51% 1D
Market Cap $5.5B
1M Return +12.85%
1Y Return +494.88%
Forward P/E N/M
Unified AI Score
37.5 / 100 SELL
Tech 20.0 Fund 47.0 Flow 70.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SANA -48.63% ERAS +494.88% Spread: +543.51 pp (ERAS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SANA TTM Op. Margin: 0.0% ERAS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs ERAS. Trailing 12-month operating profitability (SANA 0.0% vs ERAS 0.0%) and valuation multiples (SANA N/M vs ERAS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SANA (2) vs ERAS (3)
Institutional Metric SANA ERAS Criterion Row Winner
Market Capitalization Scale $605.3M $5.5B Larger Scale ERAS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -79.5% -48.7% Higher ROE ERAS
52-Week Range Position Momentum 1% ($2โ€“$5) 58% ($2โ€“$24) Stronger Trend ERAS
Beta / 30D Volatility Risk Regime 1.82ฮฒ ยท 78% Vol 2.30ฮฒ ยท 80% Vol Lower Realized Risk SANA
Unified Institutional Score Composite Signal 44.3 / 100 (HOLD) 37.5 / 100 (SELL) Higher Composite SANA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SANA vs ERAS Buy Guide
SANA BREAKDOWN
57d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live SANA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ERAS BREAKDOWN
87d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live ERAS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SANA nor ERAS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.